Navigation Links
ISS Recommends Pharmion Shareholders Vote for Merger With Celgene
Date:2/26/2008

All Four Leading Independent Proxy Advisory Firms Recommend Pharmion

stockholders vote FOR merger with Celgene

Special Meeting of Shareholders Scheduled For March 6, 2008 Pharmion Corp. Urges All Shareholders to Vote FOR the Proposed Merger

BOULDER, Colo., Feb. 26 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced that Institutional Shareholder Services (ISS) has recommended that Pharmion stockholders vote FOR the merger agreement with Celgene Corporation (Nasdaq: CELG) at the Special Stockholders Meeting scheduled for March 6, 2008. With this recommendation, all four of the leading proxy advisory firms, ISS, Glass Lewis & Co., PROXY Governance, Inc. and Egan-Jones Proxy Services, have now recommended that Pharmion stockholders support the merger with Celgene.

"We are pleased that ISS, as well as the other leading independent proxy advisory firms -- Glass Lewis & Co., PROXY Governance and Egan-Jones Proxy Services -- have all recognized the strategic and economic logic of our merger with Celgene," said Patrick Mahaffy, Pharmion's president and chief executive officer. "ISS' conclusions confirm our conviction that the merger offers the best value to Pharmion stockholders."

ISS is a leading independent U.S. proxy advisory firm and its voting analyses and recommendations are relied upon by hundreds of major institutional investment funds, mutual funds and fiduciaries throughout the country.

The Board of Directors of Pharmion unanimously recommends that stockholders vote "FOR" the approval and adoption of the agreement and plan of merger, and the approval of the merger as described in the proxy statement/prospectus and the supplement thereto.

About Pharmion

Pharmion Corporation is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Additional Information about the Transaction and Where to Find It

This press release shall not constitute an offer of any securities for sale. The acquisition will be submitted to Pharmion's stockholders for their consideration. In connection with the acquisition, Celgene and Pharmion have filed with the SEC a registration statement, a proxy statement/prospectus (which was mailed to Pharmion stockholders on or about February 6, 2008), a supplement thereto (which was mailed to Pharmion stockholders on or about February 19, 2008), and other relevant documents concerning the merger. Investors and stockholders of Celgene and Pharmion are urged to read the registration statement, the proxy statement/prospectus, the supplement thereto and other relevant documents filed with the SEC, as well as any amendments or supplements to such documents because they contain important information about Celgene, Pharmion and the merger. The proxy statement/prospectus, the supplement thereto, the registration statement, other relevant materials and any other documents filed by Celgene and Pharmion with the SEC, may be obtained free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by directing a written request to: Celgene Corporation, 86 Morris Ave., Summit, New Jersey 07901, Attention: Investor Relations, or Pharmion Corporation, 2525 28th Street, Suite 200, Boulder, Colorado 80301, Attention: Investor Relations. Investors and stockholders are urged to read the proxy statement/prospectus, the supplement thereto, the registration statement and the other relevant materials before making any voting or investment decision with respect to the merger.

Participants in Solicitations

Pharmion and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from stockholders of Pharmion in connection with the merger. Information regarding Pharmion's directors and executive officers is available in Pharmion's proxy statement on Schedule 14 A for its 2007 annual meeting of stockholders, which was filed with the SEC on April 30, 2007. Additional information regarding the interests of such potential participants is included in the proxy statement/prospectus, as supplemented.


'/>"/>
SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
2. Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Boards Directors
3. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
4. Report recommends off-site disposal of secondary waste
5. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
6. Report recommends off-site disposal of secondary waste
7. Pharmion Corporation Announces 2007 Operating Results
8. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
11. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House of ... has announced that University of Maryland School of Medicine ... and University of Maryland Medical System President and CEO ... "Speaker,s Medallion," the highest honor given to the public ... Dean Reece and Mr. Chrencik for ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
Breaking Biology Technology:
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
(Date:1/8/2016)... Kingdom , Jan. 8, 2016   Bruin Biometrics, ... today announced the closing of a $9 million financing. The ... the financing will be used to accelerate the commercialization of ... early-stage pressure ulcers. United Kingdom ... Mark approval. The device,s introduction has been met with enthusiasm ...
Breaking Biology News(10 mins):